Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-9 in Mild to Moderate COVID-19 ARDS
NCT04402060Phase 2Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of APL-9 in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Apellis Pharmaceuticals. Started May 2020; status: completed.
02
Drugs
APL-9
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04402060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402060.